ProMIS Neurosciences, Inc. (PMN) Stock Forecast
PMN analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 8 analysts
- Price target
- $42.95 average of analyst targets
- Upside to target
- +427.0% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-1.26
- 52-week range
- $6.76 – $24.79
PMN analyst ratings
8 analystsNumber of analysts at each rating.
PMN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PMN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.82 | −$1.85 | −$1.79 | — | — | 2 |
| Current fiscal year (2026) | −$7.36 | −$7.49 | −$7.23 | −$31.12 | +80.0% | 2 |
| Next fiscal year (2027) | −$5.48 | −$9.48 | −$3.44 | −$7.03 | +22.1% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PMN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 7 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
PMN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PMN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | −$2.15 | −$2.13 | −$1.82 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | −$8.24 | −$8.17 | −$7.36 | — | 0 up · 0 down |
| Next fiscal year (2027) | −$5.27 | −$5.88 | −$5.60 | −$5.60 | −$5.48 | +3.9% | 2 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PMN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; PMN beat in 7 of 12.
What analysts expect from PMN
8 analysts cover ProMIS Neurosciences; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $42.95, 427.0% above the latest close of $8.15. Analysts expect earnings of −$7.36 per share for 2026, +80.0% from a year earlier. For 2027 the average estimate is −$5.48 per share. ProMIS Neurosciences beat the EPS estimate in 7 of the last 12 quarters.
Related: PMN income statement, PMN key metrics, PMN chart. See the PMN stock overview for the latest quote and news.
PMN forecast FAQ
What is ProMIS Neurosciences's price target?
The average analyst price target for ProMIS Neurosciences is $42.95, 427.0% above the latest close of $8.15.
Is ProMIS Neurosciences a buy, hold or sell?
Of 8 analysts covering ProMIS Neurosciences, 6 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is ProMIS Neurosciences's EPS forecast?
Analysts forecast −$7.36 per share for 2026 (range −$7.49 to −$7.23); for 2027 the estimate is −$5.48.
When does ProMIS Neurosciences report earnings?
ProMIS Neurosciences is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-1.26.
Does ProMIS Neurosciences usually beat earnings estimates?
ProMIS Neurosciences reported EPS at or above the analyst estimate in 7 of the last 12 quarters.